Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial

Zoster Vaccine ◽

Corrigendum to ‘Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial’ [Vaccine 36 (2018) 4278–4286]

Vaccine ◽

10.1016/j.vaccine.2019.01.022 ◽

2019 ◽

Vol 37 (9) ◽

pp. 1252-1253

Author(s):

Céline Maréchal ◽

Himal Lal ◽

Airi Poder ◽

Murdo Ferguson ◽

Igwebuike Enweonye ◽

...

Keyword(s):

Randomized Trial ◽

Polysaccharide Vaccine ◽

Zoster Vaccine ◽

CLUSTER RANDOMIZED TRIAL OF THE 4 PILLARS TOOLKIT TO INCREASE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE UPTAKE AMONG ADULTS UNDER 65 YEARS WITH HIGH-RISK MEDICAL CONDITIONS

10.26226/morressier.5731f0d4d462b80292380470 ◽

2016 ◽

Author(s):

Richard Zimmerman

Keyword(s):

High Risk ◽

Randomized Trial ◽

Cluster Randomized Trial ◽

Polysaccharide Vaccine ◽

Vaccine Uptake ◽

Medical Conditions ◽

Cluster Randomized

Real-World Evidence for Regulatory Decisions: Concomitant Administration of Zoster Vaccine Live and Pneumococcal Polysaccharide Vaccine

American Journal of Epidemiology ◽

10.1093/aje/kwy076 ◽

2018 ◽

Vol 187 (9) ◽

pp. 1856-1862 ◽

Cited By ~ 4

Author(s):

Katia Bruxvoort ◽

Lina S Sy ◽

Yi Luo ◽

Hung Fu Tseng

Keyword(s):

Real World ◽

Concomitant Administration ◽

Polysaccharide Vaccine ◽

Zoster Vaccine ◽

Real World Evidence ◽

Regulatory Decisions

The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial

Vaccine ◽

10.1016/j.vaccine.2019.08.001 ◽

2019 ◽

Vol 37 (39) ◽

pp. 5877-5885

Author(s):

Ana Strezova ◽

Himal Lal ◽

Igwebuike Enweonye ◽

Laura Campora ◽

Pierre Beukelaers ◽

...

Keyword(s):

Randomized Trial ◽

Pertussis Vaccine ◽

Zoster Vaccine ◽

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial

Cancer ◽

10.1002/cncr.31909 ◽

2019 ◽

Vol 125 (8) ◽

pp. 1301-1312 ◽

Cited By ~ 14

Author(s):

Peter Vink ◽

Ignacio Delgado Mingorance ◽

Constanza Maximiano Alonso ◽

Belen Rubio‐Viqueira ◽

Kyung Hae Jung ◽

...

Keyword(s):

Randomized Trial ◽

Solid Tumors ◽

Zoster Vaccine ◽

Altered immunogenicity of 23-valent pneumococcal polysaccharide vaccine in elderly patients with diabetes who revealed lower responses to concomitant administration of BIKEN varicella zoster vaccine: Results of post hoc analysis of a randomized double-blind trial

Journal of Diabetes and its Complications ◽

10.1016/j.jdiacomp.2018.11.003 ◽

2019 ◽

Vol 33 (3) ◽

pp. 243-248

Author(s):

Atsuko Hata ◽

Taisei Ishioka ◽

Kazunori Oishi ◽

Toshiro Katayama ◽

Takayoshi Ohkubo

Keyword(s):

Concomitant Administration ◽

Polysaccharide Vaccine ◽

Double Blind Trial ◽

Zoster Vaccine ◽

Double Blind ◽

Varicella Zoster ◽

Post Hoc Analysis ◽

Patients With Diabetes ◽

Post Hoc

No Increased Risk of Herpes Zoster After Concomitant Administration of Zoster Vaccine and Pneumococcal Polysaccharide Vaccine

Open Forum Infectious Diseases ◽

10.1093/ofid/ofw172.615 ◽

2016 ◽

Vol 3 (suppl_1) ◽

Cited By ~ 1

Author(s):

Hung Fu Tseng ◽

Yi Luo ◽

Lina Sy ◽

Sara Tartof ◽

Rulin Hechter ◽

...

Keyword(s):

Herpes Zoster ◽

Concomitant Administration ◽

Polysaccharide Vaccine ◽

Zoster Vaccine ◽

Increased Risk

The Adjuvanted Recombinant Zoster Vaccine Co-Administered with the 13-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥50 Years: a Randomized Trial

Journal of Infection ◽

10.1016/j.jinf.2021.12.033 ◽

2021 ◽

Author(s):

Ji-Young Min ◽

Agnes Mwakingwe-Omari ◽

Megan Riley ◽

Lifeter Yenwo Molo ◽

Jyoti Soni ◽

...

Keyword(s):

Randomized Trial ◽

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Zoster Vaccine ◽

VACCINATING OLDER ADULTS IN JAPAN WITH 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) OR NO VACCINATION (NOVAC): A COST-EFFECTIVENESS ANALYSIS

10.26226/morressier.5731f0d6d462b8029237fcb3 ◽

2016 ◽

Author(s):

Yiling Jiang

Keyword(s):

Older Adults ◽

Cost Effectiveness ◽

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Cost Effectiveness Analysis ◽

Polysaccharide Vaccine ◽

Effectiveness Analysis

Pneumococcal Polysaccharide Vaccine

ADULTS 70-89 WITH HEART DISEASE, LUNG DISEASE OR DIABETES MELLITUS HAVE AN ANTIBODY RESPONSE COMPARABLE TO HEALTHY ADULTS 70-89 AFTER RECEIVING 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE

10.26226/morressier.5731f0d6d462b8029237fbe8 ◽

2016 ◽

Author(s):

Melvin Kohn

Keyword(s):

Diabetes Mellitus ◽

Heart Disease ◽

Antibody Response ◽

Lung Disease ◽

Polysaccharide Vaccine ◽

Healthy Adults ◽